Ruxolitinib Cream Approved for Children Aged 2-11 With AD
Ruxolitinib is the first topical JAK inhibitor approved in the US for pediatric AD.
Medscape Medical News
source https://www.medscape.com/viewarticle/ruxolitinib-cream-approved-children-aged-2-11-atopic-2025a1000ow3?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/ruxolitinib-cream-approved-children-aged-2-11-atopic-2025a1000ow3?src=rss
Comments
Post a Comment